(Q43560581)

English

Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

0 references

quality of life

1 reference

based on heuristic

inferred from title

author name string

Remick SC

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sedransk N

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Haase RF

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Blanchard CG

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Ramnes CR

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Nazeer T

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Mastrianni DM

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Dezube BJ

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

publication date

1 March 2001

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

178-188

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line.

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Cytokines alter production of HIV-1 from primary mononuclear phagocytes

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Non-Hodgkin's lymphoma in a population with or at risk for acquired immunodeficiency syndrome: indications for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

AIDS-related malignant lymphoma: results of prospective treatment trials

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Lymphomas in men at high risk for acquired immune deficiency syndrome (AIDS). A study of 21 cases.

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

AIDS-associated non-Hodgkin's lymphoma in San Francisco

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Retrovirus and malignant lymphoma in homosexual men.

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen.

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Clinical comparison of the nitrosoureas

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Drugs 5 years later: procarbazine

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Cancer patients and their pjysicians in the perception of psychological symptoms

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

The prevalence of psychiatric disorders among cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Malignant Lymphomas in Patients With or at Risk for AIDS in Italy: Italian Cooperative Group for AIDS- Related Tumor,*

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986)

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

AIDS-related lymphoid neoplasia. The memorial hospital experience

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1002%2F1096-8652%28200103%2966%3A3%3C178%3A%3AAID-AJH1042%3E3.0.CO%3B2-H

21 January 2018

Identifiers

10.1002/1096-8652(200103)66:3<178::AID-AJH1042>3.0.CO;2-H

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43560581&oldid=2100792617"